Aurobindo Pharma now has a total of 138 abbreviated new drug application (ANDA) approvals from the USFDA
Aurobindo Pharma said it has received final approval from the US health regulator to market and manufacture Ramipril Capsules, used for treating hypertension, in the American market.
The company has received approval from the US Food and Drug Administration (USFDA) for Ramipril Capsules in strengths of 1.25mg, 2.5mg, 5mg and 10mg, Aurobindo Pharma said in a statement.
Ramipril Capsules, which are the generic equivalent of King Pharmaceuticals Altace, are indicated for the treatment of hypertension and falls under the cardiovascular therapeutic segment, it said.
"The product has a market size of approximately $95 million for the twelve months ending September 2010, according to IMS and will be launched soon," the company said.
The Hyderabad-based firm now has a total of 138 abbreviated new drug application (ANDA) approvals from the USFDA, it said.
On Friday, Aurobindo Pharma ended 2.77% down at Rs175 on the Bombay Stock Exchange, while the benchmark Sensex declined 0.63% to 18,268.54.
Inside story of the National Stock Exchange’s amazing success, leading to hubris, regulatory capture and algo scam
Fiercely independent and pro-consumer information on personal finance.
1-year online access to the magazine articles published during the subscription period.
Access is given for all articles published during the week (starting Monday) your subscription starts. For example, if you subscribe on Wednesday, you will have access to articles uploaded from Monday of that week.
This means access to other articles (outside the subscription period) are not included.
Articles outside the subscription period can be bought separately for a small price per article.
Fiercely independent and pro-consumer information on personal finance.
30-day online access to the magazine articles published during the subscription period.
Access is given for all articles published during the week (starting Monday) your subscription starts. For example, if you subscribe on Wednesday, you will have access to articles uploaded from Monday of that week.
This means access to other articles (outside the subscription period) are not included.
Articles outside the subscription period can be bought separately for a small price per article.
Fiercely independent and pro-consumer information on personal finance.
Complete access to Moneylife archives since inception ( till the date of your subscription )
